ArticleEBioMedicine2016
A Transcriptomic Biomarker to Quantify Systemic Inflammation in Sepsis - A Prospective Multicenter Phase II Diagnostic Study.
Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- The Diagnostic Utility of Host RNA Biosignatures in Adult Patients With Sepsis: A Systematic Review and Meta-Analysis.Critical care explorations · 2025Pooled it
- T Cell- and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically Ill Patients and in Patients with Cancer.Journal of immunology (Baltimore, Md. : 1950) · 2019Trial
- Community-Acquired Pneumonia: Disease Course Prediction With a 5-Gene Signature.CHEST pulmonary · 2026Article
- Co-regulation of microglial subgroups in Alzheimer's amyloid pathology: Implications for diagnosis and drug development.PloS one · 2025Article
- Transcriptional pathways of terminal differentiation in high- and low-density blood granulocytes in sepsis.Journal of inflammation (London, England) · 2024Article
- CPVL suppresses metastasis of nasopharyngeal carcinoma through inhibiting epithelial-mesenchymal transition.Journal of cancer research and clinical oncology · 2023Article
- The 'analysis of gene expression and biomarkers for point-of-care decision support in Sepsis' study; temporal clinical parameter analysis and validation of early diagnostic biomarker signatures for severe inflammation andsepsis-SIRS discrimination.Frontiers in immunology · 2023Article
- Multiplex quantification of C-terminal alpha-1-antitrypsin peptides provides a novel approach for characterizing systemic inflammation.Scientific reports · 2022Article
- Knowledge gaps in late-onset neonatal sepsis in preterm neonates: a roadmap for future research.Pediatric research · 2022Review
- CPVL promotes glioma progression via STAT1 pathway inhibition through interactions with the BTK/p300 axis.JCI insight · 2021Article
- Two Faces of Macrophages: Training and Tolerance.Biomedicines · 2021Review
- Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?Antioxidants (Basel, Switzerland) · 2021Review
- Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques.Communications biology · 2021Article
- Use of IFNγ/IL10 Ratio for Stratification of Hydrocortisone Therapy in Patients With Septic Shock.Frontiers in immunology · 2021Article
- Discovery and Validation of Urinary Molecular Signature of Early Sepsis.Critical care explorations · 2020Article
- The cellular basis of organ failure in sepsis-signaling during damage and repair processes.Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2020Review
- Design of a Multiplexed Analyte Biosensor using Digital Barcoded Particles and Impedance Spectroscopy.Scientific reports · 2020Article
- An immune-cell signature of bacterial sepsis.Nature medicine · 2020Article
- Crocetin Attenuates Sepsis-Induced Cardiac DysfunctionFrontiers in physiology · 2020Article
- Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting.Inflammation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of a dysregulated immune response discriminates sepsis from uncomplicated infection. Currently used biomarkers fail to describe simultaneously occurring pro- and anti-inflammatory responses potentially amenable to therapy. Marker candidates were screened by microarray and, after transfer to a platform allowing point-of-care testing, validated in a confirmation set of 246 medical and surgical patients. We identified up-regulated pathways reflecting innate effector mechanisms, while down-regulated pathways related to adaptive lymphocyte functions. A panel of markers composed of three up- (Toll-like receptor 5; Protectin; Clusterin) and 4 down-regulated transcripts (Fibrinogen-like 2; Interleukin-7 receptor; Major histocompatibility complex class II, DP alpha1; Carboxypeptidase, vitellogenic-like) described the magnitude of immune alterations. The created gene expression score was significantly greater in patients with definite as well as with possible/probable infection than with no infection (median (Q25/Q75): 80 (60/101)) and 81 (58/97 vs. 49 (27/66), AUC-ROC=0.812 (95%-CI 0.755-0.869), p<0.0001). Down-regulated lymphocyte markers were associated with prognosis with good sensitivity but limited specificity. Quantifying systemic inflammation by assessment of both pro- and anti-inflammatory innate and adaptive immune responses provides a novel option to identify patients-at-risk and may facilitate immune interventions in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.